Search Results - liver+cancer

7 Results Sort By:
STING Agonist 8803 for Blood-Brain Barrier Opening in Glioblastoma Treatment
SHORT DESCRIPTION Chemical compound that opens the blood-brain barrier to enhance delivery of therapeutics for treating glioblastoma. INVENTORS Amy Heimberger* Northwestern University Feinberg School of Medicine, Department of Neurological Surgery * Principal Investigator NU 2025-212 IP...
Published: 4/29/2026   |   Updated: 4/27/2026   |   Inventor(s):  
Keywords(s): AD - Alzheimer’s Disease, Adjunct therapy, ALS - Amyotrophic Lateral Sclerosis, Animal Model, Autoimmune disease, Bladder cancer, Brain cancer, Breast cancer, Cancer Treatment, Cancer/Oncology, Cervical cancer, CNS - Central Nervous System, Colon cancer, Drug delivery, Endometrial cancer, Gastric cancer, GBM - Glioblastoma, Head and neck cancer, Immunology, Immunotherapy, Liver cancer, Lung cancer, MS - Multiple Sclerosis, Neurodegenerative disease, Neurologic disease, Ovarian cancer, Pancreatic cancer, PD - Parkinson's Disease, Prostate cancer, Repurposed Drugs, Research tool, Small molecule, Targeted therapy, TBI - Traumatic brain injury, Therapeutics
Category(s): Life Sciences > Therapeutics, Life Sciences > Biomarkers & Biomedical Research Tools
New Lipiodol Formulation for Treating Hepatocellular Carcinoma with Transarterial Chemoimmunoembolization
NU 2021-148 INVENTORS Dong Hyun Kim* Heegon Kim SHORT DESCRIPTION A new Lipiodol formulation designed to improve the efficacy and safety of transarterial chemoembolization in combination with immunotherapy. BACKGROUND Transarterial chemoembolization...
Published: 12/11/2025   |   Updated: 9/4/2024   |   Inventor(s):  
Keywords(s): Cancer/Oncology, Drug delivery, Immunotherapy, Liver cancer, Therapeutics
Category(s): Life Sciences > Therapeutics
A Viral Exposure Signature to Define and Detect Early Onset Hepatocellular Carcinoma
Summary: NCI seeks proposals from parties interested in co-development and licensing opportunities to employ biomarker viral exposure signature in diagnostic assays of early onset HCC. Description of Technology: Early detection of liver cancer, such as hepatocellular carcinoma (HCC), is key to improve cancer-related mortality. More than 800,000 people...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Xin Wei Wang, Jinping Liu, Wei Tang
Keywords(s): Biomarker, HCC, hepatocellular carcinoma, Liver cancer, viral infection, Wang
Category(s): Collaboration Sought > Licensing, Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Diagnostics
Single-domain monoclonal antibodies for the treatment of hepatocellular carcinoma
Abstract: The National Cancer Institute seeks parties to license human monoclonal antibodies and immunoconjugates and co-develop, evaluate, and/or commercialize large-scale antibody production and hepatocellular carcinoma (HCC) xenograft mouse models. An advantage of these monoclonal antibodies as a potential therapeutic is their specificity, which...
Published: 5/14/2025   |   Updated: 8/2/2023   |   Inventor(s): Mitchell Ho, Mingqian Feng, Dimiter Dimitrov, Heungnam Kim, Wei Gao
Keywords(s): Antibody-drug Conjugate, chimeric antigen receptor, HCC, hepatocellular carcinoma, IMMUNOTOXINS, Liver cancer
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology
Development and Characterization of the SLC46A3 Knockout Mouse Line
Summary: The NCI is seeking licensees for the SLC46A3 knockout mouse line. Description of Technology: Nonalcoholic fatty liver disease is caused by several factors including 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD), an environmental contaminant. TCDD causes lipid accumulation in humans by inducing the Solute Carrier Family 46 Member 3 (SLC46A3)...
Published: 4/24/2026   |   Updated: 8/2/2023   |   Inventor(s): Frank Gonzalez, Sun Hee Yim, Jung-Hwan Kim
Keywords(s): 2, 3, 7, 8-tetracholodibenzo-p-dioxin, Gonzalez, hepatocellular carcinoma, Knockout Mouse, Liver cancer, Major Facilitator Superfamily, MFS, Nonalcoholic fatty liver disease, OBESITY, SLC46A3, Solute Carrier Family, TCDD
Category(s): TherapeuticArea > Oncology, Collaboration Sought > Licensing, Application > Research Materials, TherapeuticArea > Endocrinology
IgG4 Hinge Containing Nanobody-based CARs Targeting GPC3 for Treating Liver Cancer
Summary: Researchers at the NCI seek licensing and/or co-development research collaborations for developing new nanobody-based CAR and/or antibody-T-cell receptor therapies for treating liver cancer. Description of Technology: Hepatocellular carcinoma (HCC) is the most common type of liver cancer. Globally, HCC is the sixth most prevalent cancer...
Published: 4/23/2026   |   Updated: 8/2/2023   |   Inventor(s): Mitchell Ho, Aarti Kolluri, Nan Li
Keywords(s): ANTIBODY, cancer therapeutic, Chimeric antigen receptors (CARs), Glypican-3 (GPC3), Hepatocellular Carcinoma (HCC), HO, IgG4, Liver cancer, Macrophage, NANOBODY, Natural Killer (NK) Cell, T cell, therapeutic
Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, TherapeuticArea > Oncology, Application > Therapeutics
Bile Acids and Other Agents that Modulate the Gut Microbiome for the Treatment of Liver Cancer
Abstract: Primary liver tumors and secondary hepatic malignancies are among the leading causes of cancer-related deaths. Liver metastases account for 95% of all hepatic cancers, and the liver is the most common site for organ metastasis in the body. The gut microbiome serves an important role in antitumor immunity regulating the efficacy of chemo- and...
Published: 4/22/2025   |   Updated: 8/2/2023   |   Inventor(s): Tim Greten, Chi Ma
Keywords(s): Bile Acid, Greten, Liver cancer, Natural Killer T Cells, NKT cells
Category(s): Collaboration Sought > Collaboration, TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing